Elevance Health Q4 Earnings Rise; Guides FY26; Shares Slide Pre-Market

Elevance Health reported Q4 GAAP net income attributable to shareholders of $547 million ($2.47/share) versus $418 million ($1.81/share) a year earlier, with adjusted net income of $739 million and adjusted EPS of $3.33 beating the $3.09 consensus. Revenue rose roughly to $49.7 billion year-over-year, but the company issued cautious 2026 guidance calling for low-single-digit declines in operating revenue while forecasting at least $6.8 billion of adjusted operating gain, EPS of at least $22.30 and adjusted EPS of at least $25.50; shares were down in pre-market trade.

Analysis

Market structure: ELV’s beat on adjusted EPS ($3.33 vs $3.09 est.) but guidance for low-single-digit revenue decline implies mix or pricing headwinds rather than margin collapse — beneficiaries include reinsurers, PBMs (if pharmacy cost shifts) and investment income-sensitive insurers if rates rise; losers are revenue-driven intermediaries and any carriers with heavier Medicare Advantage concentration. Competitive dynamics favor large diversified payors (ELV, UNH, CI) that can offset premium revenue weakness with underwriting discipline and investment income; market share shifts will be incremental (hundreds of bps) not structural absent CMS policy changes. Cross-asset: expect a near-term equity volatility spike (IV +20–40%), modest upward pressure on credit spreads for regional insurers, and a slight safe-haven bid into Treasuries; higher rates would materially boost insurer investment income, partially offsetting revenue declines.

Risk assessment: Tail risks include adverse CMS Medicare Advantage rate cuts (>100 bps) or a major risk-adjustment audit leading to multi-$bn clawbacks, and a sudden reacceleration of medical cost trend (>300 bps) that would compress 2026 adjusted operating gain below the $6.8bn floor. Time horizons: immediate (days) volatility; short-term (1–3 quarters) sensitivity to enrollment and CMS signals; long-term (2–4 years) driven by MA policy, provider pricing power, and secular MA penetration. Hidden dependencies: investment income assumptions, reserve releases, and pharmacy trend exposure are masking revenue guidance; catalysts are CMS rate announcement, Q1 2026 enrollment updates, and any risk-adjustment audit findings.

Trade implications: Direct: use the pullback to size a disciplined long in ELV given adjusted EPS guide of ≥$25.50 implying ~11–12x forward, but hedge regulatory risk; target 12-month upside to $350–375 (≈15–25% from $303) if medical trend stays contained. Options: implement defined-risk bullish spread (e.g., buy Jan 2027 $300 call / sell Jan 2027 $380 call) to capture recovery with limited capital. Pair: go long ELV (1% portfolio) vs short HUM (HUM) 1% to exploit ELV’s broader commercial/Medicaid mix vs HUM’s MA concentration; expect relative outperformance of 3–6% over 6–9 months if CMS actions are neutral.

Contrarian angles: Consensus focuses on revenue decline headline while underweighting that adjusted EPS floor ($25.50) and $6.8bn operating gain imply strong margin resilience — the 6% intraday sell-off likely overreacts by 8–12% to guidance conservatism. Historical parallel: 2019 insurer guidance scares corrected as medical utilization normalized and investment income cushioned results; similarly, a 6–12 month horizon could see mean reversion. Unintended consequences: buying unhedged here risks outsized drawdown if CMS cuts MA rates >1% or pharmacy inflation accelerates beyond expectations; hedged, asymmetric long exposure is preferred.

Key Decisions for Investors

• Establish a 2–3% long position in ELV on pullbacks into $290–$305, target $350 within 9–12 months (≈15–25% upside), place a hard stop-loss at 8% below entry to limit regulatory/medical-trend shock.
• Buy a defined-risk bullish call spread: Jan 2027 ELV $300 call / Jan 2027 ELV $380 call (1:1) sized for 0.5–1% portfolio exposure to capture recovery while capping capital at premium paid.
• Implement a 1% pair trade: long ELV vs short HUM (Humana) 1% to exploit ELV’s diversified mix; expect 3–6% relative outperformance over 6–9 months, close position if spread narrows <1% or if HUM reports unexpectedly strong MA metrics.
• Monitor CMS Medicare Advantage rate announcement and state Medicaid policy changes over the next 30–60 days; if MA rates are cut by >100 bps or ELV revises adjusted operating gain below $6.8bn, reduce ELV long exposure by 50% and add downside protection (buy puts or widen call spread).